» Articles » PMID: 28751931

A Review of the Molecular Mechanisms Underlying the Development and Progression of Cardiac Remodeling

Abstract

Pathological molecular mechanisms involved in myocardial remodeling contribute to alter the existing structure of the heart, leading to cardiac dysfunction. Among the complex signaling network that characterizes myocardial remodeling, the distinct processes are myocyte loss, cardiac hypertrophy, alteration of extracellular matrix homeostasis, fibrosis, defective autophagy, metabolic abnormalities, and mitochondrial dysfunction. Several pathophysiological stimuli, such as pressure and volume overload, trigger the remodeling cascade, a process that initially confers protection to the heart as a compensatory mechanism. Yet chronic inflammation after myocardial infarction also leads to cardiac remodeling that, when prolonged, leads to heart failure progression. Here, we review the molecular pathways involved in cardiac remodeling, with particular emphasis on those associated with myocardial infarction. A better understanding of cell signaling involved in cardiac remodeling may support the development of new therapeutic strategies towards the treatment of heart failure and reduction of cardiac complications. We will also discuss data derived from gene therapy approaches for modulating key mediators of cardiac remodeling.

Citing Articles

Orientin: a comprehensive review of a promising bioactive flavonoid.

Fahmy M, Sadek M, Abdou K, El-Dessouki A, El-Shiekh R, Khalaf S Inflammopharmacology. 2025; .

PMID: 40056319 DOI: 10.1007/s10787-025-01690-5.


Effect of Dapagliflozin on Ventricular Arrhythmic Events in Heart Failure Patients With an Implantable Cardioverter Defibrillator.

De Masi De Luca G, Palama Z, Longo S, Barba F, Robles A, Nesti M Cardiol Res. 2025; 16(2):140-152.

PMID: 40051671 PMC: 11882230. DOI: 10.14740/cr2018.


Exercise Training After Myocardial Infarction Enhances Endothelial Progenitor Cells Function via NRG-1 Signaling.

Huang H, Huang G, Li R, Wei L, Yuan Z, Huang W Cardiovasc Toxicol. 2025; 25(3):411-426.

PMID: 39893285 DOI: 10.1007/s12012-025-09967-5.


Targeting Macrophage Phenotype for Treating Heart Failure: A New Approach.

Shi M, Yuan H, Li Y, Guo Z, Wei J Drug Des Devel Ther. 2024; 18:4927-4942.

PMID: 39525046 PMC: 11549885. DOI: 10.2147/DDDT.S486816.


Effect of alantolactones on cardiac parameters of animals under artificially induced oxidative stress.

Fatima M, Andleeb H, Rehman T, Gul O, Azeezz S, Rehman H Biomedicine (Taipei). 2024; 14(3):12-22.

PMID: 39386184 PMC: 11460572. DOI: 10.37796/2211-8039.1457.


References
1.
Chen Y, Wang Y, Chen J, Chen X, Cao W, Chen S . Roles of transcriptional corepressor RIP140 and coactivator PGC-1α in energy state of chronically infarcted rat hearts and mitochondrial function of cardiomyocytes. Mol Cell Endocrinol. 2012; 362(1-2):11-8. DOI: 10.1016/j.mce.2012.03.023. View

2.
Talameh J, McLeod H, Adams Jr K, Patterson J . Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new. J Card Fail. 2012; 18(4):338-49. DOI: 10.1016/j.cardfail.2012.01.002. View

3.
Biala A, Kirshenbaum L . The interplay between cell death signaling pathways in the heart. Trends Cardiovasc Med. 2014; 24(8):325-31. DOI: 10.1016/j.tcm.2014.08.002. View

4.
Wahlquist C, Jeong D, Rojas-Munoz A, Kho C, Lee A, Mitsuyama S . Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature. 2014; 508(7497):531-5. PMC: 4131725. DOI: 10.1038/nature13073. View

5.
Peruzzi M, De Falco E, Abbate A, Biondi-Zoccai G, Chimenti I, Lotrionte M . State of the Art on the Evidence Base in Cardiac Regenerative Therapy: Overview of 41 Systematic Reviews. Biomed Res Int. 2015; 2015:613782. PMC: 4484838. DOI: 10.1155/2015/613782. View